Navigation Links
Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
Date:9/25/2008

SAN DIEGO, Sept. 25 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced that Dr. Dennis Kim has joined the Company as Senior Vice President and Head of Obesity and Metabolic Disorders. Dr. Kim will be leading the clinical development activities for the Company's obesity franchise.

"I am thrilled to be joining the team at Orexigen at such an exciting time," said Dr. Kim. "I'm looking forward to working with the leadership team at Orexigen to bring to market our two obesity treatment candidates, Contrave(R) and Empatic(TM)."

Dr. Kim brings more than seven years of pharmaceutical experience to Orexigen. He joins the Company from EnteroMedics, Inc., where he served as Chief Medical Officer and Vice President of Medical Affairs. Prior to that, Dr. Kim worked at Amylin Pharmaceuticals where he was Executive Director, Corporate Strategy. There, he played a significant role in the Company's alliance with Eli Lilly, including the development and launch of Byetta(R).

Dr. Kim holds an M.D. from the Chicago Medical School. He completed his internal medicine residency at Rush Presbyterian St. Luke's Medical Center and an endocrinology fellowship at the University of California, San Diego (USCD) School of Medicine. Dr. Kim also holds a Master of Business Administration degree from UCSD's Rady School of Business.

"Orexigen focuses on expertise, experience and excellence in addressing senior management positions," said Gary Tollefson, M.D., Ph.D., Orexigen President and CEO. "Dr. Kim will be a key addition to Orexigen, bringing not only a deep expertise in obesity and metabolic disorders to the Company, but also a strong background in strategy, medical affairs and management."

The Senior Vice President and Head of Obesity and Metabolic Disorders is a new position at Orexigen. Dr. Kim will report to Eduardo Dunayevich, M.D., Chief Medical Officer.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
2. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
3. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... international society for optics and photonics , are commending the U.S. Congress and ... the signing Friday by the President of the American Innovation and Competitiveness Act ...
(Date:1/11/2017)... Ca (PRWEB) , ... January 11, 2017 , ... ... in pathogens are observed in clinical settings, it is becoming increasingly clear that ... An over-reliance on culture-based methods, the standard in the study of clinical resistance, ...
(Date:1/11/2017)... PA (PRWEB) , ... January 11, 2017 , ... ... entrepreneur can make all the difference when navigating the challenges young businesses face. ... tap into the extensive expertise and experience of Geoff DiMasi, Founder and Principal ...
(Date:1/11/2017)... ... January 11, 2017 , ... Advanced Polymer Monitoring Technologies (APMT) ... Bartylla will lead European initiatives for APMT’s product lines serving polymer and biopharmaceutical ... to European manufacturers and researchers. Bernhard brings significant experience in our application areas ...
Breaking Biology Technology:
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
(Date:12/16/2016)... , Dec. 16, 2016 The global wearable medical ... 12.14 billion by 2021 from USD 5.31 billion in 2016, at ... ... mainly driven by technological advancements in medical devices, launch of a ... preference for wireless connectivity among healthcare providers, and increasing focus on ...
(Date:12/15/2016)... Mich. , Dec. 15, 2016  There is ... car doors or starting the engine. Continental will demonstrate ... Las Vegas . Through the combination ... Start and Entry) and biometric elements, the international technology ... of vehicle personalization and authentication. "The integration ...
Breaking Biology News(10 mins):